TS Nexgen

At a glance

TS Nexgen filed 51 disclosures in the last 12 months, including 1 5% holder. The most recent key filing was on Mar 19.

Revenue for 2025 was ₩14.5B, down 32.4% on 2024. It made an operating loss of ₩5.9B. Debt was 99% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩5.8B and operating loss of ₩252.3M.

The 2025 annual report lists 53 employees with an average tenure of 9.1 years and average pay of ₩72.5M, #531 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩53M each on average. It paid no cash dividend for 2025. 시스코바이오투자조합 and related parties held 3.82% at year end.

From the 2025 annual report

Staff: 53 (46 men, 7 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.8B. Directors and auditors: 9, paid ₩481M in total.

No cash dividend was paid for 2025.

Largest shareholder

시스코바이오투자조합 holds 3.82%; with 0 related parties the group holds 3.82% of common shares at year end (from 7.53% at the start of the year).

Auditor: 예지회계법인 · opinion: Qualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary